Management of Atrial Fibrillation
All patients with atrial fibrillation should be managed using the AF-CARE pathway: address Comorbidities and risk factors, Avoid stroke with anticoagulation, Reduce symptoms through rate or rhythm control, and Evaluate dynamically over time 1.
Immediate Priorities
1. Stroke Prevention with Anticoagulation
Prescribe direct oral anticoagulants (DOACs) - apixaban, dabigatran, edoxaban, or rivaroxaban - for all patients with CHA₂DS₂-VA score ≥2, and consider anticoagulation for score = 1 1. DOACs are superior to warfarin except in patients with mechanical heart valves or mitral stenosis 1.
- Use full standard DOAC doses unless specific dose-reduction criteria are met
- If using warfarin, maintain INR 2.0-3.0 and keep time in therapeutic range >70% 1
- Switch from warfarin to DOAC if there is risk of intracranial hemorrhage or poor INR control 1
Common pitfall: Do NOT use bleeding risk as a reason to permanently withhold anticoagulation 2. Instead, assess bleeding risk factors to identify and modify them (e.g., uncontrolled hypertension, excessive alcohol use, NSAIDs).
For patients truly unable to tolerate long-term anticoagulation with CHADS₂ ≥2 or CHA₂DS₂-VASc ≥3, percutaneous left atrial appendage occlusion (Watchman device) provides an alternative 3.
2. Aggressive Comorbidity and Risk Factor Management
Treat the following conditions aggressively as they directly reduce AF burden and recurrence 1:
- Hypertension: Use ACE inhibitors or ARBs (44% reduction in AF incidence in heart failure patients) 1
- Heart failure with reduced ejection fraction:
- Obesity: Weight loss reduces AF episodes 4
- Diabetes mellitus: Optimize glycemic control 1
- Obstructive sleep apnea: Treat, though CPAP hasn't shown definitive AF prevention benefit 1
- Alcohol intake: Reduce or eliminate, especially if consuming >60 g/day (men) or >40 g/day (women) 1
- Physical inactivity: Encourage moderate aerobic exercise (avoid extreme endurance athletics which increase AF risk 2.5-fold) 1
3. Symptom Control: Rate vs. Rhythm Strategy
For symptomatic patients, prioritize rhythm control (restoration and maintenance of sinus rhythm) over rate control, as newer guidelines emphasize rhythm control benefits 5. However, the choice depends on patient age, symptom severity, and AF duration 4.
Rate Control Strategy
Use when:
- Patient is older (≥65 years) with minimal symptoms 4
- Long-standing persistent AF where rhythm control has failed
- Patient preference after shared decision-making
Target heart rate:
- Resting: <110 bpm (lenient control) is acceptable for most
- During activity: Assess adequacy during exercise, not just at rest 4
- Critical: Prolonged uncontrolled ventricular rate causes tachycardia-mediated cardiomyopathy 4, 6
Medications for rate control:
- First-line: Beta-blockers OR non-dihydropyridine calcium channel blockers (diltiazem, verapamil) 4
Rhythm Control Strategy
Use when:
- Younger patients (<60 years) 4
- Highly symptomatic despite rate control
- First episode or paroxysmal AF
- Tachycardia-mediated cardiomyopathy present
Antiarrhythmic drug selection prioritizes safety over efficacy 4:
- Choice depends on underlying structural heart disease
- Catheter ablation is now first-line therapy for paroxysmal AF 1, 7 and should be considered early rather than as second-line treatment only
Important: Complete elimination of AF is not required - reduction in frequency and duration with significant quality of life improvement is a successful outcome 4.
Dynamic Reassessment
- Reassess CHA₂DS₂-VA score periodically as stroke risk changes over time 1
- Monitor for treatment-related complications
- Be willing to switch between rate and rhythm control strategies if initial approach fails 6
- Emergency room visits are rarely necessary - most AF management occurs in outpatient settings 2
When to Refer to Cardiology/Electrophysiology
- Consideration for catheter ablation (especially paroxysmal AF)
- Failed antiarrhythmic drug therapy
- Hemodynamically unstable AF
- Consideration for LAA occlusion device
- Complex cases with multiple comorbidities requiring specialized management